Spotlight on Availability of First Skin Test for Accurate Diagnosis of Alzheimer’s Disease: June is Alzheimer’s & Brain Awareness Month

SYNAPS Dx is pleased to join other leading health organizations and individuals to help raise awareness of the value of accurate, early diagnosis of Alzheimer’s Disease (AD) during June, Alzheimer’s & Brain Awareness Month. This important event shines a light on brain disorders, including AD as well as other dementias, as a major public health issue.

Today, providers and patients will be excited to learn about the availability of DISCERN™, a diagnostic test that assesses the factors directly related to the formation of synaptic connections in the brain impacting loss of memory and cognition in people living with AD, as well as regulators of amyloid plaque and tau formation—hallmarks of AD at autopsy.

Value of Early Diagnosis

In people recently diagnosed with dementia, an early diagnosis of AD is key to identifying and implementing interventions when they are more likely to have a greater impact on the course of the disease. Disease-modifying agents capable of reversing initial pathological changes is an area of urgent research. Early AD diagnosis provides an opportunity to participate in these clinical trials and, ultimately, gain a better chance of benefiting from treatment. 

An accurate test also gives providers, patients and their families a reliable answer about AD to provide a more focused patient journey and enables appropriate reimbursement for treatment.

Closer Look at DISCERN

DISCERN™, which has demonstrated 95% sensitivity and 95% specificity in the diagnosis and management of AD in people recently diagnosed with dementia, combines three biomarkers: Morphometric Imaging to measure fibroblasts’ ability to form networks; Protein Kinase C ε to measure synaptic growth; and AD-Index to measure phosphorylation of ERK1 and ERK2 in response to bradykinin.

We recently presented clinical utility data demonstrating that most clinicians are not satisfied with the current diagnostic pathway and welcome a more objective test. With a more definitive test like DISCERN™ to inform their diagnosis, clinicians were more confident implementing their care plans for people with AD.

To learn more visit here.